Success examples
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity

Chen L., Liang Z., Mao J., Liao Z., Liu Y., Ou D., Liu C., Li Z.

J Med Chem. 2025, May 19. Online ahead of print.

DOI
PubMed
Success examples
Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID

Shrestha S., Maitland M. E. R., Jing L., Duan S., Nie D. Y., St-Germain J., Barsyte-Lovejoy D., Arrowsmith C. H., Raught B.

bioRxiv 2025, 14.648778.

BRD7/BRD9 PROTAC SMARCA2 PROTAC
DOI
Success examples
Oxidation of low-density lipoprotein by hemoglobin causes pulmonary microvascular endothelial barrier dysfunction through lectin-like oxidized LDL receptor 1

Meegan J. E., Riedmann K. J., Gonski S., Douglas J. S., Bogart A. M., Ware L. B., Bastarache J. A.

Am J Physiol Lung Cell Mol Physiol. 2025, 328(5):L748-L755.

LOX-1 inhibitor
DOI
PubMed
General literature
Empowering research in chemical biology and early drug discovery - an update from the European research infrastructure EU-OPENSCREEN

Harmel R. K., Miletic T., Herzog K., Stechmann B.

SLAS Discov. 2025, 32:100228.

DOI
PubMed
Success examples
The lung microvasculature promotes alveolar type 2 cell differentiation via secreted SPARCL1

Panza P., Kim H-T., Lautenschläger T., Piesker J., Günther S., Alayoubi Y., Cleaver O., Looso M., Stainier D. Y. R.

Stem Cell Reports. 2025, 20(4):102451.

IKKβ inhibitor
DOI
PubMed
Success examples
Spatio-temporal control of mitosis using light via a Plk1 inhibitor caged for activity and cellular permeability

von Glasenapp V., Almeida A. C., Chang D., Gasic I., Winssinger N., Gotta M.

Nat Commun. 2025, 16(1):1599.

PLK1 inhibitor
DOI
PubMed